GENMAB Buy scenarioI am loking to get into a buy at best after the downward trendline is broken and the SMA(89) is crossed to the upside afterwards.
See examples in the past as indicated by my green circles...
Leave a like or comment, please
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
10.73 USD
644.20 M USD
2.44 B USD
60.34 M
About GENMAB A/S
Sector
CEO
Jan G. J. van de Winkel
Headquarters
Copenhagen
Website
Founded
1998
ISIN
DK0010272202
FIGI
BBG000CR1YT9
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Watch out for long position in GenmabGenmab has reached an important area, which before in time have been a good time to start a long postion.
Genmap Correction -40 %I like Genmab. The stock was one of my long positions for many years. I went into cash in the fall of 2021. After minus 40 percent, I will now gradually add to Genmab again.
Genmab is a era done ?I have sold all of my genmab shares i started to buy at the start of corona, 5 year tmeframe i think we see a head an shoulder formation an hoping to buy again 15-1600 kr :)
in the stockHello again, i bought this stock last year at like 1500 kr, but unf. i see a Head an should forming in think it will fall a little back, of course i hope im wrong an go up from here :) An not selling holding at least 5-20 years :)
Inverse Cup and handle on the weekly $GMABInverse Cup and handle on the weekly $GMAB
- Inverse Cup and handle on the weekly
- VPVR acting as resistance
- Waiting for a trigger
Interesting cup with handle developmentLooks like we have a cup with handle. Potential target 3600-3800
Genmab opportunitysteamloss in the Genmab stock will likely fuel a new rush.
1) the 2 previous times times RSI has been below 30, it has resulted in strong returns. Will it happen a 3rd time?
2) The current strongly rising RSI will like make sure that the price will move and stay above the short term downward trend
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where GNMSF is featured.
Frequently Asked Questions
The current price of GNMSF is 205.25 USD — it has decreased by −3.55% in the past 24 hours. Watch Genmab A/S stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Genmab A/S stocks are traded under the ticker GNMSF.
GNMSF stock has fallen by −8.52% compared to the previous week, the month change is a −8.38% fall, over the last year Genmab A/S has showed a −33.03% decrease.
We've gathered analysts' opinions on Genmab A/S future price: according to them, GNMSF price has a max estimate of 493.69 USD and a min estimate of 231.65 USD. Watch GNMSF chart and read a more detailed Genmab A/S stock forecast: see what analysts think of Genmab A/S and suggest that you do with its stocks.
GNMSF reached its all-time high on Sep 2, 2021 with the price of 500.92 USD, and its all-time low was 3.30 USD and was reached on Dec 3, 2009. View more price dynamics on GNMSF chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
GNMSF stock is 5.47% volatile and has beta coefficient of 0.22. Track Genmab A/S stock price on the chart and check out the list of the most volatile stocks — is Genmab A/S there?
Today Genmab A/S has the market capitalization of 13.66 B, it has decreased by −2.14% over the last week.
Yes, you can track Genmab A/S financials in yearly and quarterly reports right on TradingView.
Genmab A/S is going to release the next earnings report on Feb 12, 2025. Keep track of upcoming events with our Earnings Calendar.
GNMSF earnings for the last quarter are 2.96 USD per share, whereas the estimation was 3.13 USD resulting in a −5.62% surprise. The estimated earnings for the next quarter are 3.49 USD per share. See more details about Genmab A/S earnings.
Genmab A/S revenue for the last quarter amounts to 826.75 M USD, despite the estimated figure of 843.31 M USD. In the next quarter, revenue is expected to reach 882.29 M USD.
GNMSF net income for the last quarter is 188.93 M USD, while the quarter before that showed 201.77 M USD of net income which accounts for −6.36% change. Track more Genmab A/S financial stats to get the full picture.
No, GNMSF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 13, 2024, the company has 2.20 K employees. See our rating of the largest employees — is Genmab A/S on this list?
Like other stocks, GNMSF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Genmab A/S stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Genmab A/S technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Genmab A/S stock shows the sell signal. See more of Genmab A/S technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.